Emtriva: New Formulation and Labeling Changes

September 28, 2005

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

On September 28, 2005, The Food and Drug Administration approved EMTRIVA (emtricitabine) Oral Solution 10 mg/mL. The approval of this Oral Solution formulation allows for dosing recommendations in pediatric patients. EMTRIVA is now indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in patients over three months of age.

In addition the following changes to the label were made: (Please refer to the attached PDF document for specific details)

Clinical Pharmacology Section

Pharmacokinetic data in pediatrics, renal impairment information and results from a drug-drug interaction study with zidovudine were included.

Indications and Usage

The indication was expanded to include patients over three months of age.



Addition of zidovudine to the drug interactions section, addition of the immune reconstitution syndrome section, updated carcinogenicity data and pediatric use statements were included.

Adverse Reactions

This section was updated to include data in pediatric patients.

Dosage and Administration

This section was revised to include dosing information in pediatric patients with the oral solution and capsule formulations. In addition, dosing information for the oral solution for adult patients was included. A new table was added to include dose adjustment information in adults with renal impairment for the capsule and oral solution formulations.

How Supplied

Data on storage conditions for the Oral Solution were included.

This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.